Vicor Technologies, Inc. (OTCBB: VCRT)

With the latest press release we are face to face with the benefits of experienced management in terms of the business side of science.

We know a large physician shareholder base represents the early adoptees of this Company.

In anticipation of the product launch in early 2010, Vicor identified several of the Company’s physician shareholders and their practices for early adoption of the PD2i Analyzer™.  The goal was to obtain crucial feedback. Physician acceptance is a critical success factor.  This week press release indicates this crucial information:

The PD2i Analyzer™ is being well received among physicians.

This is great news and a tremendous reflection on management.

The Company’s strategy has always been to establish a large physician base – 350 shareholders and 450 members of the Company’s National Cardiac Panel – as early adopters of the Company’s technology to ensure that:

• The product is well received by physicians interested in Vicor’s success
• Product enhancement suggestions provided by these early adopters can be incorporated into the technology before a national rollout.

The Company’s recent press release indicates EXPERIENCED LEADERSHIP HAS PAID OFF.

Vicor indicated the Company continues to execute their business plan for ongoing marketing efforts and sales of the PD2i Analyzer™, which is being well received among physicians.

Vicor is also on target for the completion of clinical efforts directed at additional 510(k) submissions, which should lead to an acceleration of marketing efforts once granted.

Access to an archive of analyzable data such as that provided by the MUSIC Trial — which is fairly uncommon — provided Vicor with the tremendous opportunity to quickly and cost-effectively produce a dataset, which is believed will be of sufficient statistical significance to support an application for sudden cardiac death in a claim to the FDA for 510(k) marketing clearance.

Vicor Technologies, Inc. (OTCBB: VCRT) is in the crucial transformative stage for a biotechnology company on the verge of becoming a viable commercial enterprise.

Vicor’s Three Products Employing the PD2i™ Nonlinear Algorithm.

• PD2i Analyzer(TM) has FDA 510(k) marketing clearance. It measures Heart Rate Variability. Physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes.
• PD2i VS(TM) (Vital Sign) stratifies risk in combat and civilian trauma victims and is in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research. (http://www.usaisr.amedd.army.mil/)
• PD2i CA(TM) (Cardiac Analyzer) identifies patients at risk of sudden cardiac death and is in multiple clinical trials.

Vicor Technologies, Inc.
2300 NW Corporate Blvd.
Suite 123
Boca Raton, FL 33431
877.528-PD2i (7324)
info@vicortech.com

Disclaimer and Forward-Looking Statements
The appearance of name-brand institutions or products in this profile does not constitute endorsement by the U.S. Army Institute of Surgical Research, the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense or the U.S. Government of the information, products or services contained therein.

Forward-looking statements in this profile are based on current plans and expectations that are subject to uncertainties and risks, which could cause the Company’s future results to differ materially. The following factors, among others, could cause the Company’s actual results to differ: the Company’s ability to obtain FDA approval of the PD2i VS™ (Vital Sign) for military and civilian applications and the PD2i CA™ (Cardiac Analyzer), the Company’s ability to continue to receive financing sufficient to continue operations and complete the critical clinical trials; the Company’s ability to continue as a going concern; the Company’s ability to successfully develop products based on the Company’s technologies, included but not limited to the Company’s ASP distribution model for the PD2i Analyzer™; the Company’s ability to obtain and maintain adequate levels of third-party reimbursement for the Company’s products; the impact of competitive products and pricing; the Company’s ability to receive regulatory approval for the Company’s products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for the Company’s technologies; the ability of third-party manufacturers to manufacture the Company’s products; the Company’s ability to retain the services of the Company’s key personnel; the Company’s ability to market and sell the Company’s products successfully; the Company’s ability to protect the Company’s intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and Vicor assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Pentony Enterprises LLC is STOCKGURU.COM. 10604 Robincreek Lane; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC was compensated fifty thousand restricted common shares and seventy-two hundred dollars by the company for profile coverage for the period ending March 31, 2010. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. We will not be buying or selling shares of Vicor during the promotional period.

Medizone International, Inc. (OTCBB: MZEI) (http://medizoneint.com)

Monday’s Medizone Press Release noted that the  AsepticSure™ system is capable of decontamination to the previously unobtainable 6 log standard on all hospital surfaces, hard or soft.

This incredible kill rate included fabric in addition to procelain, formica and stainless steel.

“Fabric exposure requires an additional 15 minutes to achieve the same 6 log kill rate, which represents a full turn around for a thorough cleaning of about 95 minutes for all surface materials.”

This has got to be a hospital administrator’s dream.   Can you imagine the financial consequence of just one hospital buying group adopting the AsepticSure™ system?

Can you imagine how many hospitals will make this their standard.

NO ONE ELSE IS DOING THIS.  I CHALLENGE YOU TO FIND ANY OTHER  COMPANY DELIVERING THIS.  EMAIL ME IF YOU DO.

THIS IS AN AMAZING OPPORTUNITY WITH A RELIABLE, CREDIBLE ON THE MONEY COMPANY.

Contact information:
Medizone International, Inc. (OTCBB: MZEI)
(See Medizone International Video)
http://www.medizoneint.com

Telephone: 415-868-0300
Fax: 415-868-2344
Address:
Post Office Box 742
Stinson Beach, CA 94970

Pentony Enterprises LLC is STOCKGURU.COM, SHAREHOLDERVISION.COM and STREETRESEARCH.COM. 9555 Lebanon Road; Suite 103; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC was compensated seventy-two hundred dollars and 450,000 144 restricted common shars by the company for profile coverage for the period ending September 15, 2009. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Medizone International, Inc. (OTCBB: MZEI) (http://medizoneint.com)

Just the Facts! This is a reminder of how much the AsepticSure™ sterilization system is needed in hospitals.  I wanted to take a detailed look at the recent Duke University Study on MRSA.

Monday’s Medizone Press Release noted that the  AsepticSure™ system is capable of decontamination to the previously unobtainable 6 log standard on all hospital surfaces, hard or soft. This incredible kill rate included fabric in addition to porcelain, formica and stainless steel.

The cost-saving potential for community hospitals is enormous based on the recent Duke University Medical Center Report which undeniably indicates MRSA leads to staggering expenses for surgical patients.

The study conducted a multi-center study of multiple surgical procedure types among 659 patients to determine clinical and financial outcomes of surgical site infections that are directly attributable to MRSA (methicillin-resistant Stapylococcus aureus).  The impact of methicillin-resistance on surgical patients was found to be substantial, preventing a single case of surgical site infection due to MRSA can potentially save hospitals as much as $60,000 per case.

This is a dream scenario for MZEI.

Deverick J. Anderson, M.D., MPH, an infectious diseases specialist at Duke University Medical Center was the lead author of the study.

The study concluded that given the estimated cost of one MRSA case, a $60,000 intervention to prevent even one of these infections would be cost-effective for an institution.

The study noted:  With this new financial data, greater emphasis should be placed on an effort to design and evaluate specific preventative interventions.

For the seven hospitals examined the total estimated cost resulting from surgical site infections due to MRSA was more than $19 million.

Contact information:
Medizone International, Inc. (OTCBB: MZEI)
(See Medizone International Video)
http://www.medizoneint.com

Telephone: 415-868-0300
Fax: 415-868-2344
Address:
Post Office Box 742
Stinson Beach, CA 94970

Pentony Enterprises LLC is STOCKGURU.COM, SHAREHOLDERVISION.COM and STREETRESEARCH.COM. 9555 Lebanon Road; Suite 103; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC was compensated seventy-two hundred dollars and 450,000 144 restricted common shars by the company for profile coverage for the period ending September 15, 2009. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Medizone International, Inc. (OTCBB: MZEI) (http://medizoneint.com)

This is the Company that Never Sleeps!  What an amazing week.  No question about it — if there ever was a biotech that CAN this is it.

Today in their press release we learn that eliminating the “Super Bug” from stainless steel is a huge deal.  AsepticSure™ can reliably achieve 6 log (99.9999%) kill or greater on Porcelain and Formica as well as stainless surfaces AND it can do it in thirty minutes.

The AsepticSure™ system is capable of decontamination to the previously unobtainable 6 log standard on all hospital surfaces, hard or soft.

Then we learn:  Stainless steel represents an FDA standard test surface.

This is why I believe in this company, totally.  They are competent and directed and moving rapidly toward two goals:

1.  Commercialization

2.  Peer Reviewed Journal Articles

As you know they have their own B2SLA Laboratory at a leading Research University.

NO ONE ELSE IS DOING THIS.  I CHALLENGE YOU TO FIND ANY OTHER  COMPANY DELIVERING THIS.  EMAIL ME IF YOU DO.

THIS IS AN AMAZING OPPORTUNITY WITH A RELIABLE, CREDIBLE ON THE MONEY COMPANY.

Contact information:
Medizone International, Inc. (OTCBB: MZEI)
(See Medizone International Video)
http://www.medizoneint.com

Telephone: 415-868-0300
Fax: 415-868-2344
Address:
Post Office Box 742
Stinson Beach, CA 94970

Pentony Enterprises LLC is STOCKGURU.COM, SHAREHOLDERVISION.COM and STREETRESEARCH.COM. 9555 Lebanon Road; Suite 103; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC was compensated seventy-two hundred dollars and 450,000 144 restricted common shars by the company for profile coverage for the period ending September 15, 2009. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Giant Step Forward for AsepticSure™

San Francisco, March 16, 2010 Medizone International, Inc., (MZEI.OB) announces a giant step forward for the AsepticSure™ hospital sterilization system. Edwin Marshall, Medizone’s Chief Executive Officer explained, “A week ago we announced completing the first full round of room scale trials eliminating all pathogens across the ‘Super Bug’ spectrum on stainless steel surfaces. While it may seem counterintuitive, stainless is one of the more difficult surfaces to fully sterilize when contaminated with these highly resistant bacteria. Stainless also represents an FDA standard test surface. Today, we are announcing further developments that should have tremendous commercial implications relative to hospital acceptance of AsepticSure™ as the new standard in providing greatly enhanced patient safety.

Test results from our second stage of ‘room scale’ trials have clearly demonstrated that AsepticSure™ can reliably achieve 6 log (99.9999%) kill or greater on Porcelain and Formica as well as stainless surfaces. These materials represent the majority of all hospital surfaces. Utilizing a unique additional technology that is protected under our original patent filing of July 13, 2009, we have also demonstrated 6 log reductions with many common fabrics. Thus, it now appears the AsepticSure™ system is capable of decontamination to the previously unobtainable 6 log standard on all hospital surfaces, hard or soft.

Of commercial significance in a hospital setting, we are now able to greatly reduce the time required to achieve 6 log kills on hard surfaces to 30 minutes of exposure. With the charge time and destruct time for reuse of the space factored in, that translates to a room turn around time of 80 minutes, a 40 minute saving in total turn around time from our original target of 2 hours. Fabric exposure requires an additional 15 minutes to achieve the same 6 log kill rate, which represents a full turn around for a thorough cleaning of about 95 minutes for all surface materials.”

“This reduction in room turn around time from 120 minutes to 95 minutes for a thorough sterilization will be viewed very favorably by hospitals,” stated Dr. Michael Shannon, Medizone’s Director of Medical Affairs, who continued, “Any significant reduction in treatment time to put a room back into service is critical to hospital flow patterns. Given the sum of our results, it now appears that a typical protocol might have a hospital perform a first cleaning of 95 minutes to fully sterilize the space, which would be followed by cleanings, perhaps as infrequently as one time per week for lower risk settings, requiring only 80 minutes to complete. Not only is AsepticSure™ continuing to demonstrate its superlative antimicrobial efficacy, it is increasingly becoming apparent that it will be viewed as a practical necessity easily managed by trained hospital maintenance staff without putting rooms out of service for unacceptable periods of time.”

Medizone International, Inc., is a research and development company engaged in developing its AsepticSure™ System to decontaminate and sterilize hospitals, sports training facilities, schools and other critical infrastructure. A government variant is being developed for bio-terrorism counter measures. Successful decontamination by AsepticSure™ to the 6 log standard or greater has been demonstrated with C.difficile, E coli, Pseudomonas aeruginous, MRSA, VRE and Bacillius subtilis.

This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

Investor Relations: 415-868-0300

E-mail: operations@medizoneint.com

Medizone International’s 10K has been released.

Medizone is devoted to transparency and shareholder communication.

I think this is just another example.

Hospital beta testing is expected to begin by late spring at sites in both the US and Canada.  At this time it is indicated that the first peer reviewed journal article will published which is expected to be this summer.

Last week’s Chairman’s Message delivered crucial information to the shareholders and I wanted to re-iterate that:

• Hospital beta testing is expected to begin by late spring at sites in both the US and Canada
• The first peer reviewed journal article will published which is expected to be this summer
• Commercialization will begin shortly thereafter

Contact information:
Medizone International, Inc. (OTCBB: MZEI)
(See Medizone International Video)
http://www.medizoneint.com

Telephone:  415-868-0300
Fax:  415-868-2344
Address:
Post Office Box 742
Stinson Beach, CA 94970

Pentony Enterprises LLC is STOCKGURU.COM, SHAREHOLDERVISION.COM and STREETRESEARCH.COM. 9555 Lebanon Road; Suite 103; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC was compensated seventy-two hundred dollars and 450,000 144 restricted common shars by the company for profile coverage for the period ending September 15, 2009. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Vicor Technologies, Inc. (OTCBB: VCRT) has a strong scientific foundation and has been embraced internationally.

This Company is led by a team with incredible experience.  They know what they are doing.

You want to know that the fantastic science Vicor brings to the table will not fail because of lack of business experience.

I am a huge fan of the fact that their initial roll out was designed to deliver feed back to the company.

Vicor is in the very advanced stages for a Bio-Tech holding.

Management and Scientific Advisory Board

David H. Fater
President, Chief Executive Officer, Chief Financial Officer, Director

Joined Vicor in 2002, from ALDA & Associates International Inc., a business and financial consulting firm specializing in healthcare and life sciences.

Prior to forming ALDA & Associates in 1993, Mr. Fater held senior executive positions with three public healthcare companies. He led the initial public offering process for BMJ Medical Management, Inc. (1997-1999) and Community Care of America (1995-1996), and led Coastal Physician Group, Inc. (1993-1995) to a NYSE listing and $1 Billion market capitalization. Before this, Mr. Fater was employed by Ernst & Young, where he completed his 24-year tenure as a Senior International Partner advising senior management and boards of directors (1969-1992).

Mr. Fater is a certified public accountant in Georgia, Illinois, North Carolina, and New York. He holds a BS in Accounting from the University of North Carolina.

James E. Skinner, Ph.D.
Vice President, Director of Grant Research, Director

Founding Vicor in August, 2000, Dr. Skinner has extensive experience both as a scientist and manager of large research and development projects. He is the Director of the Delaware Water Gap Science Institute, a non-profit medical research organization devoted to the development of medical devices and pharmaceuticals. Prior to founding the Delaware Water Gap Science Institute, Dr. Skinner was Associate Director of the Totts Gap Medical Research Laboratories, Inc. (1969-1997). Earlier, he was a Professor and Researcher at Baylor College of Medicine in Houston (1969-1993) and recipient of numerous research grants from the National Institutes of Health.

Dr. Skinner holds a PhD in Neuroscience from the University of California at Los Angeles and a BA in Pre-Med, Physics, and Physiological Psychology from Pomona College.

Jerry M. Anchin, Ph.D.
Vice President, Director of Research and Development, Director

Dr. Anchin has more than 30 years of experience in the fields of immunology, molecular biology, drug discovery and protein chemistry. Prior to founding Vicor in 2000, Dr. Anchin was employed by Ciblex Pharmaceuticals (1998-2000), where he became group leader of the drug discovery program that led to the discovery of novel small molecules for use in the prevention of asthma. Earlier, he held positions at Prism Pharmaceuticals (1996-1998), and Immuno Pharmaceuticals (1993-1996). Before that, he was Head of Assay Development and Manufacturing at International Immunoassay Labs (1991-1998), where he was instrumental in designing a novel assay for the detection of the protein creatine kinase released during acute myocardial infarction.

Dr. Anchin holds patents for 14 immunoassay and drug discovery platforms; he has an additional 16 patents pending. Dr. Anchin earned a PhD in Immunology from Texas A&M University and a BA in Cell Biology from the University of California at Santa Barbara.

Daniel N. Weiss, M.D., F.A.C.C.
Chief Medical Officer

With Vicor since 2004, Dr. Weiss has extensive experience as a practicing cardiologist and electrophysiologist. He is a partner in Florida Arrhythmia Consultants and was the director of several hospital electrophysiology laboratories. He has also served as a consultant to several Fortune 500 medical device companies, including Medtronic, St. Jude Medical and Guidant. In addition, he served as clinical investigator in the MADIT-II (MultiCenter Automatic Defibrillator Implantation Trial) and SCDHeFT (Sudden Cardiac Death Heart Failure Trial) clinical trials.

Dr. Weiss received his MD with Distinction in Research from the Mount Sinai School of Medicine where he received the Nathan A. Seltz Award for research in Cardiovascular and Renal Disease. He holds a BSE cum laude in Electrical Engineering and Computer Science from Princeton University.

Thomas J. Bohannon
Chief Accounting Officer

Thomas J. Bohannon was appointed to serve as the Chief Accounting Officer of the Company effective as of December 28, 2008. Mr. Bohannon has been in the accounting and financial field for more than 40 years. Mr. Bohannon worked as a senior manager at Ernst & Young in Atlanta from 1968 until 1978 where he specialized in financial and SEC reporting before becoming the partner in charge of audit and review services for Pappadakis, Nelson & Bohannon from 1978-1991. Since 1992, he has focused on his own consulting practice, serving as the financial officer for a variety of companies in the Southeast United States.

The current directors of the Company are David H. Fater (2002) and James E. Skinner (2000) (Class I), Jerry M. Anchin (2003) and Frederick M. Hudson (2008) (Class II), and Dr. Edward Wiesmeier (2004)and Joseph C. Franchetti (2008) (Class III). The Class I Directors’ term expires at the 2011 Annual Meeting. The Class II Directors’ term expires at the 2012 Annual Meeting. The Class III Directors’ term expires at the 2010 Annual Meeting.

Edward Wiesmeier, MD

Dr. Wiesmeier has been a member of the Company’s board of directors since October 2004. From 1974 to 2007, Dr. Wiesmeier was at UCLA where during that time he served as Clinical Professor of Obstetrics & Gynecology at the UCLA School of Medicine and Assistant Vice Chancellor for Student Development and Health. Presently he is Clinical Professor/Voluntary in the Dept. of Reproductive Medicine at the UCSD School of Medicine. Dr. Wiesmeier serves as Chairman of the Company’s Scientific Advisory Board.

Frederick M. Hudson

At the time of his retirement from KPMG, Mr. Hudson was a partner in charge of the firm’s Mid-Atlantic Health Care Practice (1969-2006). He is a Director on the Board of Financial Administration of the Catholic Archdiocese of Baltimore, the Board of Sponsors of Loyola College Sellinger School of Business and Management, and the Board of Trustees of the Maryland Historical Society. He is Chairman of the Audit Committee of the Board of Directors of Paradigm Management Services, LLC, and Remedi Health Services, Inc., and a member of the Audit and Finance Committee of the Board of Directors of GBMC Healthcare, Inc., and its affiliate, the Greater Baltimore Medical Center. Mr. Hudson is a graduate of Loyola College.

Joseph C. Franchetti

Mr. Franchetti is, and has been, a consultant, director, and advisor to several healthcare/medical device companies, including start-ups, in the cardiology/cardiovascular and life sciences areas. He is currently Vice Chairman of CVAC Health Systems, Inc. Earlier, he was President and Chief Executive Officer of Cohn Medical Instruments Corp. (now Omron), a Japanese-owned, global leader in non-invasive blood pressure, and physiological and vital sign monitoring and diagnosis. He founded and was Chief Executive Officer of Bio-Chem Laboratory Systems Inc., and a Corporate and International Vice President and General Manager for Technicon (now Siemens) and Narco Scientific (now Respirionics). He is a Trustee Emeritus of Southwest Research Institute of Texas. Mr. Franchetti is a graduate of the Wharton School of the University of Pennsylvania.

Scientific Advisory Board

Vicor’s Scientific Advisory Board gives it access to some of the most accomplished professionals in the life sciences. In addition to others, Vicor’s Scientific Advisory Board includes such significant thought leaders as:

Mark E. Josephson, MD

• Chief of Cardiology, Beth Israel Deaconess Medical Center
• One of the world’s leading experts on arhythmias
• Author, Clinical Cardiac Electrophysiology
• Scientific advisor to over twenty companies

Hein J. J. Wellens, MD

• Chairman & Professor, Cardiology Department, Academisch Ziekenhuis Maastricht, the Netherlands
• Director, Interuniversity Cardiology Institute
• Member, Netherlands Academy of Arts and Sciences
• Visiting Lecturer, Harvard Medical School.

Richard M. Luceri, MD, FACC

• Recently retired Director, Interventional Arrhythmia Center, Holy Cross Hospital
• Clinical Investigator, MADIT-II (MultiCenter Automatic Defibrillator Implantation Trial)
• Author, SCD-HeFT (Sudden Cardiac Death Heart Failure Trial).

Robert G. Hauser, MD, FACC, FHRS

• Senior Consulting Cardiologist, Minneapolis Heart Institute
• Chairman, Cardiovascular Services Division, Abbott Northwestern Hospital.
• Former CEO, Cardiac Pacemakers, Inc. (Eli Lilly subsidiary acquired by Guidant Corporation)

Jonathan Kaplan, MD, MPH

• Medical Director, Fidelis Care New York
• Former Corporate Medical Director, Excellus Blue Cross Blue Shield.

David Chazanovitz

• Former President/CEO, Alveolus, Inc.
• Former CEO, Cambridge Heart, Inc.

Edward F. Lundy, MD, PhD

• Chief of Cardiothoracic Surgery, Active International Cardiovascular Institute at Good Samaritan Hospital
• Ph.D. in physiology with focus on altered states physiologies (hibernation)
• Accomplished trauma surgeon

Vicor Technologies, Inc.
2300 NW Corporate Blvd.
Suite 123
Boca Raton, FL 33431
877.528-PD2i (7324)
info@vicortech.com

Disclaimer and Forward-Looking Statements
The appearance of name-brand institutions or products in this profile does not constitute endorsement by the U.S. Army Institute of Surgical Research, the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense or the U.S. Government of the information, products or services contained therein.

Forward-looking statements in this profile are based on current plans and expectations that are subject to uncertainties and risks, which could cause the Company’s future results to differ materially. The following factors, among others, could cause the Company’s actual results to differ: the Company’s ability to obtain FDA approval of the PD2i VS™ (Vital Sign) for military and civilian applications and the PD2i CA™ (Cardiac Analyzer), the Company’s ability to continue to receive financing sufficient to continue operations and complete the critical clinical trials; the Company’s ability to continue as a going concern; the Company’s ability to successfully develop products based on the Company’s technologies, included but not limited to the Company’s ASP distribution model for the PD2i Analyzer™; the Company’s ability to obtain and maintain adequate levels of third-party reimbursement for the Company’s products; the impact of competitive products and pricing; the Company’s ability to receive regulatory approval for the Company’s products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for the Company’s technologies; the ability of third-party manufacturers to manufacture the Company’s products; the Company’s ability to retain the services of the Company’s key personnel; the Company’s ability to market and sell the Company’s products successfully; the Company’s ability to protect the Company’s intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and Vicor assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Pentony Enterprises LLC is STOCKGURU.COM. 10604 Robincreek Lane; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC was compensated fifty thousand restricted common shares and seventy-two hundred dollars by the company for profile coverage for the period ending March 31, 2010. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. We will not be buying or selling shares of Vicor during the promotional period.

Vicor Technologies, Inc. (OTCBB: VCRT)  Vicor Profile Stock Guru

This is a bio-tech company that HAS GOT IT ALL.

I understand that these words sound like an overstatement but when you look at the Publications, the Field Trials and the Presentations associated with Vicor you realize — this is NOT an overstatement:

Vicor Technologies is Delivering

A NEW VITAL SIGN

With the Ability to Save Lives in Combat and Civilian Settings

As a predictor of sudden cardiac death it has been shown to be highly accurate, with a sensitivity approaching 100% and a specificity of ~86%.

No stress-testing or any active participation from the patient is required.

A large physician shareholder base represents the early adoptees of this Company.

The PD2i™ Nonlinear Algorithm has been cleared by the FDA for marketing as a measure of Heart Rate Variability and already has a billing code — so providers can be paid.

Vicor’s PD2i™ Nonlinear Algorithm

The PD2i Analyzer™ can capture and display Heart Rate Variabilityin patients at rest and during paced respiration and controlled exercise.

• Able to identify trauma victims in need of an immediate lifesaving intervention
• Able to be used along with other clinical data to identify patients at risk of sudden cardiac death
• Able to be used along with other clinical data to identify patients who have autonomic dysfunction
• Able to improve trauma triage in real world situations and on the battlefield where time is of the essence and the collection of ‘clean’ data is never guaranteed
• Able to provide consistently accurate results which requires just one to two minutes of EKG data in a trauma setting
• Not derailed in delivering actionable results by noisy raw EKG data
• Functional in trauma environments and battlefield situations

Vicor’s Three Products Employing the PD2i™ Nonlinear Algorithm.

• PD2i Analyzer(TM) has FDA 510(k) marketing clearance. It measures Heart Rate Variability. Physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes.
• PD2i VS(TM) (Vital Sign) stratifies risk in combat and civilian trauma victims and is in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research. (http://www.usaisr.amedd.army.mil/)
• PD2i CA(TM) (Cardiac Analyzer) identifies patients at risk of sudden cardiac death and is in multiple clinical trials.

This image is important because it demonstrates how EASY it is to use the PD2i Analyzer™.  This truly is A NEW VITAL SIGN.

The PD2i Analyzer™ has been cleared by the FDA for marketing as a measure of Heart Rate Variability. It quantifies the relationship between the patient’s heart and brain by measuring the heart rate variation over time. The PD2i® test is painless and much like a value-added electrocardiogram. Adhesive sensor pads are placed on the skin and for the next twenty minutes the Analyzer records heartbeat information. Exercise is not necessary during the test.

The PD2i Analyzer™ twenty-minute test is composed of recording a sequence of one thousand heartbeats. The PD2i™ nonlinear algorithm is subsequently applied to that recording in order to find subtle patterns in the resulting data, yielding the final result which is expressed as a minimum PD2i™ value.

Vicor Technologies, Inc.
2300 NW Corporate Blvd.
Suite 123
Boca Raton, FL 33431
877.528-PD2i (7324)
info@vicortech.com

Disclaimer and Forward-Looking Statements
The appearance of name-brand institutions or products in this profile does not constitute endorsement by the U.S. Army Institute of Surgical Research, the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense or the U.S. Government of the information, products or services contained therein.

Forward-looking statements in this profile are based on current plans and expectations that are subject to uncertainties and risks, which could cause the Company’s future results to differ materially. The following factors, among others, could cause the Company’s actual results to differ: the Company’s ability to obtain FDA approval of the PD2i VS™ (Vital Sign) for military and civilian applications and the PD2i CA™ (Cardiac Analyzer), the Company’s ability to continue to receive financing sufficient to continue operations and complete the critical clinical trials; the Company’s ability to continue as a going concern; the Company’s ability to successfully develop products based on the Company’s technologies, included but not limited to the Company’s ASP distribution model for the PD2i Analyzer™; the Company’s ability to obtain and maintain adequate levels of third-party reimbursement for the Company’s products; the impact of competitive products and pricing; the Company’s ability to receive regulatory approval for the Company’s products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for the Company’s technologies; the ability of third-party manufacturers to manufacture the Company’s products; the Company’s ability to retain the services of the Company’s key personnel; the Company’s ability to market and sell the Company’s products successfully; the Company’s ability to protect the Company’s intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and Vicor assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Pentony Enterprises LLC is STOCKGURU.COM. 10604 Robincreek Lane; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC was compensated fifty thousand restricted common shares and seventy-two hundred dollars by the company for profile coverage for the period ending March 31, 2010. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. We will not be buying or selling shares of Vicor during the promotional period.

Yesterday, after a strong down trade based on a wrong perception, Medizone International’s Chairman addressed the issue.

This presents a great opportunity to acquire this stock at a discounted price.

In paraphrasing the Chairman’s Message I have deduced these crucial facts:

• Hospital beta testing is expected to begin by late spring at sites in both the US and Canada
• The first peer reviewed journal article will published which is expected to be this summer
• Commercialization will begin shortly thereafter

There are no fundamental problems here.  Basically, the unexpected success of the kill rate necessitated the need to modify the equipment.

The most important facts taken from Yesterday’s Chairman’s Message are:

It has been brought to my attention by shareholders there has recently been some misunderstanding as to development path time frames for AsepticSure™. This message is intended to hopefully clear up those perceived misunderstandings.

Hospital beta testing is expected to begin by late spring at sites in both the US and Canada.  At this time it is indicated that the first peer reviewed journal article will published which is expected to be this summer.

As you will recall on January 5, 2010, MZEI announced “Test results achieved over the past two months now predictably demonstrate greater than 6 logs of bacterial “kill” across the full spectrum of hospital contaminants including MRSA, C difficile, E coli, Pseudomonas aeruginosa and VRE in addition to the internationally accepted surrogate for Anthrax, Bacillus subtilis.”

Those first 6-log results achieved in their laboratory unit greatly enhanced the efficacy or the AsepticSure™ product.  This enhanced technology has not yet been integrated into their full-scale equipment.

The development stage machinery required additional engineering prior to being ready for hospital beta testing and production.

Currently, utilizing the expanded and enhanced design team that is experienced in bringing products from the research stage to full production, Medizone is finalizing the design of a new, fully integrated AsepticSure™ system for hospital beta testing.

This design is intended to deliver a product into the hospital beta test environment that maintenance staff within the hospital can easily be taught to use with equipment that is 100% reliable.

Medizone noted the expectation that sales should flow smoothly out of a successful beta test program.

Medizone has achieved results in both laboratory and room scale trials that are absolutely unheard of in the scientific and medical communities. The same success in commercialization is expected.

I reiterate my belief that MZEI should be a core holding and it this is a great price.

Contact information:
Medizone International, Inc. (OTCBB: MZEI)
(See Medizone International Video)
http://www.medizoneint.com

Telephone:  415-868-0300
Fax:  415-868-2344
Address:
Post Office Box 742
Stinson Beach, CA 94970

Pentony Enterprises LLC is STOCKGURU.COM, SHAREHOLDERVISION.COM and STREETRESEARCH.COM. 9555 Lebanon Road; Suite 103; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC was compensated seventy-two hundred dollars and 450,000 144 restricted common shars by the company for profile coverage for the period ending September 15, 2009. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Chairman’s Message
Shareholder Update

March 11, 2010

It has been brought to my attention by shareholders there has recently been some misunderstanding as to development path timeframes for AsepticSure™. This message is intended to hopefully clear up those perceived misunderstandings.

The end of 2008 and going into early 2009 the company believed it would finalize product development by the end of 2009 with first deliveries during the first quarter of 2010. That has obviously proven to be an overly optimistic time frame, and I accept responsibility for not being more conservative with our projections at that time. Those projections were based on statements made to me by our development partner that the prototype equipment being planned for full-scale room treatment “would be very close to a production prototype.” This clearly has not proven to be the case.

As projects like this involving revolutionary technology and break through science evolve, they do have a tendency to take on a life of their own. Relative to the development of the room scale prototype, initially our development partner fell behind expectations relative to delivery time. Also, and this is a very big positive, on January 5, 2010 we announced “Test results achieved over the past two months now predictably demonstrate greater than 6 logs of bacterial “kill” across the full spectrum of hospital contaminants including MRSA, C difficile, E coli, Pseudomonas aeruginosa and VRE in addition to the internationally accepted surrogate for Anthrax, Bacillus subtilis.” Those first 6-log results were achieved in our laboratory unit with technology that had not yet been integrated into our full-scale equipment. This incredible scientific accomplishment was explained in the January 10, 2010 press release relating to greatly enhanced patent protection. “This was made possible”, commented Dr Michael Shannon, Medizone’s Director of Medical Affairs, “through the integration of several complimentary technologies, each with their own antimicrobial effects, which in combination were shown not to be additive, but multiplicative.”

In sum, the goal posts had moved. Additional technologies that greatly enhanced the AsepticSure™ product now had to be integrated into a design that had not originally been considered for this additional technology that greatly enhanced efficacy. Thus, in reality, what was once intended to be “very close to a production prototype,” had clearly become a development machine that required additional engineering prior to being ready for hospital beta testing and production. During the last half of 2009, I tried to soften expectations relative to commercialization time frames in both how press releases were drafted and also with our SEC Filings. I hope this communication will clear up once and for all any misunderstanding.

Currently, utilizing an expanded and enhanced design team that is experienced in bringing products from the research stage to full production, Medizone is finalizing the design of a new, fully integrated AsepticSure™ system for hospital beta testing. This design will achieve the same results as the current beta prototype while also being a major step forward and very close to what we expect the full production prototype will be. Shareholders must comprehend, now that we understand the science and clearly understand what is required for open space sterilization such as in hospital settings, it is absolutely essential to deliver a product into the hospital beta test environment that maintenance staff within the hospital can easily be taught to use and the equipment must be 100% reliable. Anything short of that is a recipe for failure. Medizone Management from top to bottom and all of our development staff, are dedicated to that outcome; deliver a first rate, reliable machine, that hospitals can count on. Nothing less will do.

Since I want to be cautious with time frames given past slippages, hospital beta testing is expected to begin by late spring at sites in both the US and Canada. Production developments from the hospital beta system are not expected to be in the hardware or basic design, but more related to things like state of the art packaging. However, let me caution, as I stated earlier in this communication, these things do have a way of taking on a life of their own.

We believe moving from hospital beta testing to initial production and sales at modest rates should prove to be a smooth, manageable transition. We expect sales should flow smoothly out of a successful beta test program. In closing, I think it is important for shareholders to remember that Medizone has achieved results in both laboratory and room scale trials that are absolutely unheard of in the scientific and medical communities. We expect the same success in commercialization.

We are still a small company with limited resources. I am proud of what we have achieved. It is absolutely essential that we not rush this next phase of product development, as it must be done correctly the first time. I assure you both Dr Shannon, myself and all of our team, are putting our full effort into making sure that is the case.

As we successfully transition into hospital beta testing, when the first peer reviewed journal article is published (expected this summer), as partners are announced and the management team and board are expanded to reflect the skill sets of a rapidly growing commercially viable company, our contribution to science and medicine will be clear to all.

Yours truly,

Edwin G. Marshall
Chairman &
CEO
Medizone International, Inc.

This Chairman’s message contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.